| Summary: | 碩士 === 弘光科技大學 === 食品暨應用生物科技所 === 99 === The effect of ferulic (FA) and gallic (GA) acids on treatment of chronic kidney disease (CKD) has been lacking. Doxorubicin (DR, Adriamycin) was used to induce chronic kidney disease (CKD). DR significantly reduced levels of serum albumin, GOT, GPT, RBC, TNF-, and urinary creatinine, but elevated levels of serum cholesterol, TG, BUN, creatinine, uric acid, WBC, platelet count, IL-6, and urinary BUN and proteins. DRCKD rats, FA and GA significantly increased kidney weight and glomerular volume. FA reduced glomerular filtration rate but GA did not. FA enhanced more collagen deposition than GA in renal cortex and glomeruli. Both FA and GA showed crucial hyperlipidemic activity, increased serum BUN, WBC, and platelet counts, IL-6, and urinary BUN and protein; decreased GOT and GPT, and urinary creatinine. The inhibitions of matrix metalloproteinase-2 (MMP-2) by FA and GA were very comparable, although GA suppressed matrix metalloproteinase-9 (MMP-9) more effectively. Both FA and GA were moderate antioxidative prooxidants, ineffective in SOD suppression, but effective in MDA elimination. In DRCKD rats, Western blot analysis indicated that FA further upregulated CD34, -SMA, tissue pDGFR, p-PDGFR, and TGF-β; and the downregulation of p-PI3K, and p-Akt. Both PDGF-BB and TGF-β are considered to induce kidney prefibrosis stage. Regarding this, GA was only slightly more beneficial. Both PDGF-BB and TGF-β are considered to induce kidney prefibrosis stage. Regarding this, GA was only slightly more beneficial. In conclusion, long term use of GA may prevent the chronic kidney disease from progression but FA will deteriorate the disease itself.
|
|---|
